We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
McKesson (MCK) to Report Q3 Earnings: Is a Beat in the Cards?
Read MoreHide Full Article
McKesson Corporation (MCK - Free Report) is scheduled to report third-quarter fiscal 2023 results on Feb 1, after the market close.
In the last reported quarter, the company delivered an earnings surprise of 9.8%. It beat estimates in three of the trailing four quarters and missed once, the average surprise being 13.00%.
Q3 Estimates
The Zacks Consensus Estimate for McKesson’s fiscal third-quarter earnings per share is pegged at $6.34, suggesting an improvement of 3.1% from the prior-year quarter's levels. The same for revenues stands at $70.48 billion, indicating an increase of 2.7% from the year-ago reported figure.
Factors to Note
McKesson’s fiscal third-quarter performance are expected to reflect segmental strength.
The U.S. Pharmaceutical and Specialty Solutions segment might have acted as a key growth driver in the quarter to be reported. The consensus mark for this segment’s revenues is pegged at $61.7 billion, indicating an improvement of 12.1% from the prior-year quarter.
The segment is likely to have benefited from market growth and higher volumes from retail national account customers in the to-be-reported quarter. However, branded-to-generic conversions might have weighed on the segment’s performance. Nevertheless, the company’s broad spectrum of specialty biopharmaceutical providers and manufacturers is likely to have contributed to the fiscal third-quarter performance.
Growth and improvement in the primary care business and contribution from kitting, storage, and distribution of ancillary supplies to the U.S. government's COVID-19 vaccine program are likely to have positively impacted the company’s Medical-Surgical Solutions segment.
McKesson’s collaboration with the U.S. government's COVID-19 vaccine distribution effort highlighted the company’s role in the COVID-19 response. It was selected by the U.S. government as the centralized distributor of refrigerated and frozen COVID-19 vaccines and the ancillary kits used to administer those vaccines.
In July 2022, the U.S. government renewed the existing COVID-19 vaccine distribution contract. The company continues to reap benefits from its COVID-related programs in Canada and Europe.
These positive developments may get reflected in the fiscal third-quarter results.
Continued growth in the Medical-Surgical segment and Prescription Technology Solutions segment is likely to have benefited the company’s top line in the to-be-reported quarter. However, sales of COVID-19 test kits are likely to have declined during the third quarter. The Zacks Consensus Estimate for Medical-Surgical segment and Prescription Technology Solutions segment stood at $2.78 billion and $1.12 billion, respectively.
Earnings Beat Likely
Our proven model predicts an earnings beat for McKesson this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate ($6.36 per share) and the Zacks Consensus Estimate ($6.34 per share), is +0.21% for McKesson.
Here are a few other medical stocks worth considering, as these also have the right combination of elements to beat on earnings this reporting cycle:
Cardinal Health (CAH - Free Report) has an Earnings ESP of +5.75% and a Zacks Rank of 2. CAH has an estimated long-term growth rate of 11.7%.
Cardinal Health’s earnings surpassed estimates in two of the trailing four quarters and missed twice, with the average surprise being 3.04%.
Laboratory Corp. of America (LH - Free Report) has an Earnings ESP of +2.67% and a Zacks Rank #2 at present. LH has an earnings yield of 7%, which compares favorably with the industry’s yield of 4.5%.
Laboratory Corp. of America ‘s earnings surpassed estimates in three of the trailing four quarters and missed once, with the average surprise being 6.06%.
Becton, Dickinson and Company (BDX - Free Report) has an Earnings ESP of +0.17% and a Zacks Rank of 3 at present. BDX has an estimated long-term growth rate of 9.5%.
Becton, Dickinson and Company’s earnings surpassed estimates in all the trailing four quarters, with the average surprise being 10.39%.
Image: Bigstock
McKesson (MCK) to Report Q3 Earnings: Is a Beat in the Cards?
McKesson Corporation (MCK - Free Report) is scheduled to report third-quarter fiscal 2023 results on Feb 1, after the market close.
In the last reported quarter, the company delivered an earnings surprise of 9.8%. It beat estimates in three of the trailing four quarters and missed once, the average surprise being 13.00%.
Q3 Estimates
The Zacks Consensus Estimate for McKesson’s fiscal third-quarter earnings per share is pegged at $6.34, suggesting an improvement of 3.1% from the prior-year quarter's levels. The same for revenues stands at $70.48 billion, indicating an increase of 2.7% from the year-ago reported figure.
Factors to Note
McKesson’s fiscal third-quarter performance are expected to reflect segmental strength.
The U.S. Pharmaceutical and Specialty Solutions segment might have acted as a key growth driver in the quarter to be reported. The consensus mark for this segment’s revenues is pegged at $61.7 billion, indicating an improvement of 12.1% from the prior-year quarter.
The segment is likely to have benefited from market growth and higher volumes from retail national account customers in the to-be-reported quarter. However, branded-to-generic conversions might have weighed on the segment’s performance. Nevertheless, the company’s broad spectrum of specialty biopharmaceutical providers and manufacturers is likely to have contributed to the fiscal third-quarter performance.
Growth and improvement in the primary care business and contribution from kitting, storage, and distribution of ancillary supplies to the U.S. government's COVID-19 vaccine program are likely to have positively impacted the company’s Medical-Surgical Solutions segment.
McKesson’s collaboration with the U.S. government's COVID-19 vaccine distribution effort highlighted the company’s role in the COVID-19 response. It was selected by the U.S. government as the centralized distributor of refrigerated and frozen COVID-19 vaccines and the ancillary kits used to administer those vaccines.
McKesson Corporation Price and Consensus
McKesson Corporation price-consensus-chart | McKesson Corporation Quote
In July 2022, the U.S. government renewed the existing COVID-19 vaccine distribution contract. The company continues to reap benefits from its COVID-related programs in Canada and Europe.
These positive developments may get reflected in the fiscal third-quarter results.
Continued growth in the Medical-Surgical segment and Prescription Technology Solutions segment is likely to have benefited the company’s top line in the to-be-reported quarter. However, sales of COVID-19 test kits are likely to have declined during the third quarter. The Zacks Consensus Estimate for Medical-Surgical segment and Prescription Technology Solutions segment stood at $2.78 billion and $1.12 billion, respectively.
Earnings Beat Likely
Our proven model predicts an earnings beat for McKesson this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.
Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate ($6.36 per share) and the Zacks Consensus Estimate ($6.34 per share), is +0.21% for McKesson.
Zacks Rank: McKesson currently carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Other Stocks Worth a Look
Here are a few other medical stocks worth considering, as these also have the right combination of elements to beat on earnings this reporting cycle:
Cardinal Health (CAH - Free Report) has an Earnings ESP of +5.75% and a Zacks Rank of 2. CAH has an estimated long-term growth rate of 11.7%.
Cardinal Health’s earnings surpassed estimates in two of the trailing four quarters and missed twice, with the average surprise being 3.04%.
Laboratory Corp. of America (LH - Free Report) has an Earnings ESP of +2.67% and a Zacks Rank #2 at present. LH has an earnings yield of 7%, which compares favorably with the industry’s yield of 4.5%.
Laboratory Corp. of America ‘s earnings surpassed estimates in three of the trailing four quarters and missed once, with the average surprise being 6.06%.
Becton, Dickinson and Company (BDX - Free Report) has an Earnings ESP of +0.17% and a Zacks Rank of 3 at present. BDX has an estimated long-term growth rate of 9.5%.
Becton, Dickinson and Company’s earnings surpassed estimates in all the trailing four quarters, with the average surprise being 10.39%.
Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar.